Ultragenyx Pharmaceutical Financial Statements
NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ultragenyx Pharmaceutical revenue and earnings
In fiscal 2025, Ultragenyx Pharmaceutical generated $673.0 million in revenue, up 20.2% from fiscal 2024, its 9th consecutive year of revenue growth. Ultragenyx Pharmaceutical reported a net loss of $575.0 million, compared with a loss of $569.0 million a year earlier. Operating margin was -79.5%.
Diluted earnings per share came in at -$5.83. Over the last 5 fiscal years, RARE's revenue has grown at a 19.9% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Ultragenyx Pharmaceutical income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 673.00M | 560.00M | 434.00M | 363.33M | 351.41M | 271.03M | 103.71M | 51.49M | 2.61M | 133.00K |
| Revenue growth (YoY) | +20.18% | +29.03% | +19.45% | +3.39% | +29.66% | +161.32% | +101.41% | +1871.48% | +1863.91% | — |
| Cost of Revenue | — | — | — | — | — | — | — | 1.15M | 1.00K | — |
| Gross Profit | — | — | — | — | — | — | — | 50.35M | 2.61M | — |
| Operating Expenses | — | — | — | — | — | 601.15M | 527.89M | 422.87M | 331.55M | 248.14M |
| Research & Development | 750.00M | 698.00M | 648.00M | 705.79M | 497.15M | 412.08M | 357.36M | 294.00M | 231.64M | 183.20M |
| Selling, General & Admin | 349.00M | 321.00M | 310.00M | 278.14M | 219.98M | 182.93M | 161.52M | 127.72M | 99.91M | 64.94M |
| Operating Income | -535.00M | -536.00M | -569.00M | -648.92M | -381.74M | -330.12M | -424.17M | -371.37M | -328.94M | -248.01M |
| Other Income (Expense) | 1.00M | -5.00M | -1.00M | -1.57M | -1.69M | 607.00K | -787.00K | -5.59M | 6.53M | 2.17M |
| Pretax Income | -571.00M | -567.00M | -609.00M | -701.73M | -452.98M | -185.36M | -399.44M | -197.10M | -318.34M | -245.84M |
| Income Tax | 4.00M | 2.00M | -2.00M | 5.70M | 1.04M | 1.21M | 3.28M | 514.00K | -16.20M | 35.00K |
| Net Income | -575.00M | -569.00M | -607.00M | -707.42M | -454.02M | -186.57M | -402.73M | -197.61M | -302.14M | -245.87M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 |
| EPS (Diluted) | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 |
| Shares Outstanding (Basic) | 98.60M | 90.50M | 73.50M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M |
| Shares Outstanding (Diluted) | 98.60M | 90.50M | 73.50M | 69.91M | 67.80M | 60.85M | 56.58M | 49.78M | 42.45M | 39.59M |
| EBITDA | -500.00M | -500.00M | -543.00M | -630.70M | -368.50M | -317.86M | -415.63M | -351.83M | -323.12M | -244.58M |
| Gross Margin | — | — | — | — | — | — | — | 97.77% | 99.96% | — |
| Operating Margin | -79.49% | -95.71% | -131.11% | -178.60% | -108.63% | -121.80% | -408.98% | -721.18% | -12593.49% | -186471.43% |
| Net Margin | -85.44% | -101.61% | -139.86% | -194.71% | -129.20% | -68.84% | -388.31% | -383.75% | -11567.34% | -184867.67% |
This table shows 10 annual periods of Ultragenyx Pharmaceutical's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow RARE's reporting calendar. What is a income statement?